Buying an already-impaired asset — what diligence would you do, and what is the biological equivalent?
also called as-of-date diligence · representations and warranties · impairment at acquisition
A buyer never assumes an asset is in the condition the seller describes; they inspect it on the day they buy. We give menin inhibitors to children whose leukemia has already been changed by earlier treatment, and we almost never inspect the leukemia first.
The same thing, for a scientist
In an acquisition, the buyer's central problem is that the asset may already be impaired at the moment of purchase, in ways the historical record does not reveal. The response is structural: as-of-date diligence, representations and warranties about condition, and a material-adverse-change clause covering deterioration between signing and closing. The biological counterpart is uncomfortably exact. Heavily pretreated KMT2A::AFF1 samples are markedly less menin-inhibitor-sensitive than earlier samples from the same patients, despite no prior menin-inhibitor exposure, with sustained on-target transcriptional effect in the resistant cells [E1]. The drug is, in other words, frequently bought impaired. The graph records this as an open question; the diligence frame turns it into two concrete things — a quantifiable impairment index built from treatment history, and a recommendation that the asset be inspected before purchase by ex vivo sensitivity testing on the actual relapse sample.
The purchase decision, stated as a buyer would state it
A clinician deciding to give a menin inhibitor at third relapse is buying an asset whose condition they are inferring from a description written at diagnosis. The genotype (KMT2A-rearranged) is the description. The condition is whatever four lines of prior therapy have done to the cell state, and nothing in the current workup measures it.
The standard oncology counterargument is that relapse genotyping is the diligence. It is not, in this case, because the impairment observed in the serial PDX study came with no causal mutation — RAS-pathway and TP53 co-mutations emerged but were individually insufficient to induce resistance in vitro 1. A genotype-only diligence process is looking at the wrong ledger.
Three imported instruments and their biological equivalents1 deeper
- As-of-date diligence. Inspect the asset on the day of purchase. Equivalent: ex vivo drug-sensitivity testing on the relapse sample before committing the patient, which is technically routine and clinically almost never done for menin inhibitors.
- Representations and warranties about condition. The seller states the asset's condition and bears the risk if wrong. Equivalent: nothing exists. A trial enrolling relapsed patients makes no statement about, and does not measure, prior-therapy-induced impairment, so the risk sits entirely with the patient.
- Material adverse change between signing and closing. Equivalent: the interval between the decision to treat and the start of treatment, during which further cytotoxic therapy may be given as a bridge. If therapy installs impairment, bridging chemotherapy before a menin inhibitor is an unexamined harm.
The strongest argument for moving the drug earlier
If impairment accumulates with therapy, the value of the asset is highest at diagnosis and falls monotonically thereafter. That is an argument for frontline use that does not depend on any claim about efficacy — it depends only on the asset deteriorating while you wait. It arrives at the same place as hyp-menin-inhibitors-belong-frontline-in-infants by a different route, which is worth noting because independent arguments converging is weak evidence but not no evidence.
The limits of the frame
Assets in a transaction have a condition independent of the buyer; a leukemia's sensitivity is partly defined by the drug being asked about, so 'condition' is not a single quantity. A sample impaired for menin inhibition may be perfectly sensitive to a T-cell engager, which has no acquisition counterpart.
The frame also pushes toward measurement for its own sake. Ex vivo sensitivity testing is only worth doing if a different decision follows from a bad result, and in a child at third relapse with few options, it often would not. The diligence recommendation should therefore be attached to the situations where an alternative genuinely exists — chiefly when choosing between a menin inhibitor and an immunotherapy.
| domain | finance |
|---|---|
| source concept | acquisition diligence: as-of-date inspection, representations and warranties about condition, and material adverse change |
| practical recommendation | Ex vivo sensitivity testing is worth doing where an alternative genuinely exists, principally when choosing between a menin inhibitor and an immunotherapy at relapse. Testing for its own sake in a child with no alternatives is not diligence, it is delay. |
mapping
[
{
"bio": "deciding to give a menin inhibitor at relapse",
"analog": "acquiring an asset"
},
{
"bio": "the KMT2A-rearranged genotype recorded at diagnosis",
"analog": "the seller's description of the asset, written at an earlier date"
},
{
"bio": "cell state and drug sensitivity at the moment of treatment",
"analog": "the actual condition of the asset on the closing date"
},
{
"bio": "prior therapy installing menin resistance before any menin exposure",
"analog": "impairment already present at acquisition and invisible on the historical record"
},
{
"bio": "relapse genotyping",
"analog": "reviewing the title documents — necessary, and silent on condition"
},
{
"bio": "ex vivo drug-sensitivity testing on the relapse sample",
"analog": "as-of-date physical inspection, the diligence step that is currently skipped"
},
{
"bio": "bridging chemotherapy given between the decision to treat and the start of the menin inhibitor",
"analog": "material adverse change between signing and closing"
},
{
"bio": "using the drug at diagnosis rather than at relapse",
"analog": "buying the asset before it deteriorates"
}
]generated hypotheses
[ "hyp-therapy-installed-impairment-index" ]
- If therapy installs the resistance, then the standard practice of reserving new agents for later lines is systematically destroying their value, and every trial that enrols only heavily pretreated patients is measuring the drug at its worst.
- Ex vivo sensitivity testing that returns a bad result, in a child with no alternative, generates distress and delay without changing anything. The diligence recommendation must be tied to situations with a real choice.
- An impairment index built from treatment history could become a reason to deny a child a drug, on the basis of a two-patient observation. Any such index needs prospective validation before it goes anywhere near a treatment decision.
- Does cumulative cytotoxic exposure, specifically, install menin-inhibitor resistance, or is the association entirely explained by the biology of repeatedly relapsed disease?
- Is ex vivo drug-sensitivity testing for menin inhibitors feasible on the blast numbers obtainable from an infant marrow, and does it predict clinical response?
- If impairment accumulates, which therapy classes contribute most — anthracyclines, nucleoside analogues, chromatin-directed agents, or immunotherapy?
- E1moderate confidence 3 of 5: One strong study, or several smaller consistent ones.paper
In serially sampled patient-derived xenografts, heavily pretreated KMT2A::AFF1 ALL samples were much less sensitive to menin inhibition than samples taken earlier in the same patients' disease course despite no prior menin-inhibitor exposure; transcriptomics documented sustained on-target efficacy against canonical menin-inhibitor targets in the resistant cells, with emergent RAS-pathway and TP53 co-mutations individually insufficient to induce resistance in vitro and possible contributions from KMT2D downregulation and KMT2C inactivation. Two infant ALL PDX samples were sensitive.
Upfront menin-inhibitor resistance in multiply pretreated leukemias · Mahdavi L, Bernt KM, et al. · Experimental Hematology 2025What this evidence cannot show
Serial samples from two patients. This is a small observation carrying a large inference, and the whole analogy rests on it; replication is the first requirement.
Evidence that argues against this (1)
- The two infant ALL PDX samples in the same study were sensitive, so youth or early disease may protect, or the sample is simply too small to say anything. Mahdavi L et al. 2025
- E2moderate confidence 3 of 5: One strong study, or several smaller consistent ones.paper
Acquired resistance to DOT1L inhibition in paediatric KMT2A::AFF1 B-ALL produced cells that became largely independent of H3K79 methylation while still requiring DOT1L, HOXA9 and the fusion, selectively abandoning some fusion target genes and drifting myeloid — demonstrating that chromatin-directed therapy alone can install a durable adapted state.
Modelling acquired resistance to DOT1L inhibition exhibits the adaptive potential of KMT2A-rearranged acute lymphoblastic leukemia. · Schneider P, Crump NT, Arentsen-Peters STCJM, et al. · Experimental Hematology and Oncology 2023What this evidence cannot show
A different drug class and an in vitro resistance derivation. It shows adaptation is available to these cells, not that conventional chemotherapy induces it.
Evidence that argues against this (1)
- Acquired resistance derived in cultured cells under prolonged drug exposure is a strong, unphysiological selection, and independence from H3K79 methylation while still requiring DOT1L is a property of the surviving line. The published non-canonical H3K79me2-dependent survival pathways are the corroborating result worth naming here. eLife 2021
- E3strong confidence 4 of 5: Replicated in peer-reviewed work by more than one group.paper
In Interfant-06, 651 infants received intensive multi-agent chemotherapy with 6-year event-free survival of 46.1%, and high-risk infants intended for transplant frequently had early events, establishing that most children reaching a relapse setting have had substantial cumulative cytotoxic exposure.
Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study · Pieters R, De Lorenzo P, Ancliffe P, et al. · Journal of Clinical Oncology 2019What this evidence cannot show
Establishes exposure, not impairment. The link between the two is the hypothesis, not the evidence.
Evidence that argues against this (1)
- A 6-year EFS of 46.1% in 651 infants belongs to one protocol and era, and "high-risk infants intended for transplant frequently had early events" is selection by indication: the patients assigned to transplant were the ones expected to do worst. That makes the observation unusable as evidence about what transplant does. Statistics in Medicine 2006
- E4strong confidence 4 of 5: Replicated in peer-reviewed work by more than one group.paper
In 84 adults with relapsed or refractory AML after menin-inhibitor failure, 86% had been intensively pretreated and 77% were venetoclax-exposed, with overall response to next therapy of 32% and median overall survival of 4.4 months.
Outcomes of relapsed or refractory acute myeloid leukemia after menin inhibition failure · Multicentre retrospective consortium · Blood Advances 2026What this evidence cannot show
Describes the pretreated population in which menin inhibitors are currently used; it cannot separate the effect of pretreatment from the effect of being a patient who has relapsed repeatedly.
Evidence that argues against this (1)
- Eighty-four adults assembled after menin-inhibitor failure is a cohort defined by having failed, so a 32% response and 4.4-month survival describe what happens next to people who got there rather than a property installed by prior therapy. Confounding by indication runs through every number in it. Journal of Clinical Oncology 2025
- analogous to →Adaptive, non-genetic resistance — the leukemia keeps the fusion and rewires how it is maintained
pretreated disease as an asset impaired before purchase
argues for ex vivo sensitivity testing before committing a relapsed patient
generated by as-of-date diligence on an impaired asset
- analogous to →MEN1 drug-interface mutations — the first proof that a chromatin drug can drive Darwinian escape in patients
resistance that pre-dates the drug is an impaired position bought without diligence